The money a 510(k) never has to mention

A pediatric device company that has never corresponded with FDA about anything can still be spending money that started as an FDA appropriation. Section 305 of the Food and Drug Administration Amendments Act of 2007 (Public Law 110-85) authorizes exactly that structure: grants to nonprofit consortia for demonstration projects that improve pediatric device availability, not grants to the device makers themselves.

A five-year award, renewed on performance

FDA currently funds five of these consortia — among them the Consortium for Technology & Innovation in Pediatrics, the Alliance for Pediatric Device Innovation, and the Midwest Pediatric Device Consortium — each on a five-year award, continued year to year on annual appropriations and the grantee’s own performance against its workplan. The program has been reauthorized twice since 2007: through fiscal 2022 by the FDA Reauthorization Act of 2017, and through fiscal 2027 by the Food and Drug Omnibus Reform Act of 2022, enacted as Division FF of the same appropriations act that funds the agency generally.

What the consortium does with it

The grant doesn’t build a device. It funds an organization whose job is to find and support the people who will — mentoring, prototyping help, regulatory navigation, and, in most of these consortia, a direct re-grant competition of their own. A consortium runs its own pitch competition or seed-fund cycle, judged by its own reviewers, and writes checks of a few thousand to a few hundred thousand dollars straight to individual pediatric device inventors and startups. The federal award paid for the organization. The organization’s own money, by the time it reaches an inventor, is one transaction removed from Washington.

The first transfer is federal money, and it moves like any other grant. The second transfer is the consortium’s own money by then — and nothing requires that one to look like federal money at all.

Where the trail actually ends

FDA’s own program page lists which consortia hold a current award and roughly what it funds. What it does not list, and has no reason to, is which individual company received money from a given consortium’s own competition, or what that company built with it. If that company’s device later clears FDA, nothing in its 510(k) or PMA record says a federal pediatric-device grant helped build it — a 510(k) has no field for funding history, federal or otherwise, and FDA has never asked for one.

The practice

FDA Radar’s four sources start at the point a device reaches FDA for review; a grant that funded the work years earlier, through a nonprofit FDA itself created no office to run, sits entirely upstream of anything this product, or any device-clearance database, was built to see. A portfolio read that wants to know whether a competitor’s device had early federal seed money has to go looking at the consortia themselves, not at any regulatory record their eventual clearance produces. This is regulatory intelligence about where a record exists and where it doesn’t, never regulatory advice about what a specific company’s funding history means for its device.